文献速递临床试验与 GCP

机器人辅助根治性膀胱切除术联合体内尿流改道与开放根治性膀胱切除术对膀胱癌患者90天并发症和死亡率的影响:一项随机临床试验

Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

该随机临床试验在英国9个中心纳入非转移性膀胱癌患者,比较机器人辅助根治性膀胱切除术联合体内重建与开放根治性膀胱切除术的恢复和并发症。主要结局为术后90天内存活且不在院天数,机器人组中位数82天(IQR 76-84) vs 开放组80天(IQR 72-83),校正差值2.2天(95%CI 0.50-3.85;P=0.01)。机器人组血栓栓塞并发症(1.9% vs 8.3%)和伤口并发症(5.6% vs 16.0%)更少。

要点

  • 机器人组90天内存活且不在院天数中位数82天 vs 开放组80天,校正差值2.2天(95%CI 0.50-3.85;P=0.01)。
  • 机器人组血栓栓塞并发症1.9% vs 开放组8.3%,差值-6.5%(95%CI -11.4%至-1.4%)。
  • 机器人组伤口并发症5.6% vs 开放组16.0%,差值-11.7%(95%CI -18.6%至-4.6%)。

核心结论

  • 在非转移性膀胱癌接受根治性膀胱切除术的患者中,与开放根治性膀胱切除术相比,机器人辅助根治性膀胱切除术联合体内尿流改道在90天内存活且不在院天数方面有统计学显著增加,但这些发现的临床重要性仍不确定。

研究设计与样本

  • 随机临床试验,在英国9个中心招募非转移性膀胱癌患者,招募时间为2017年3月至2020年3月,随访在90天、6个月和12个月进行,最终随访日期为2021年9月23日。
  • 参与者随机接受机器人辅助根治性膀胱切除术联合体内重建(n=169)或开放根治性膀胱切除术(n=169)。
  • 338例随机参与者中,317例接受了根治性膀胱切除术(平均年龄69岁;67例女性[21%];107例[34%]接受新辅助化疗;282例[89%]接受回肠 conduit 重建);主要结局在305例(96%)中进行分析。
  • 分析对尿流改道类型和中心进行了校正。

主要发现

  • 主要结局:术后90天内存活且不在院天数中位数机器人组82天(IQR 76-84) vs 开放组80天(IQR 72-83),校正差值2.2天(95%CI 0.50-3.85;P=0.01)。
  • 血栓栓塞并发症机器人组1.9% vs 开放组8.3%,差值-6.5%(95%CI -11.4%至-1.4%)。
  • 伤口并发症机器人组5.6% vs 开放组16.0%,差值-11.7%(95%CI -18.6%至-4.6%)。
  • 开放手术组报告的生活质量较机器人手术组更差,在5周时欧洲五维五水平生活质量量表评分平均差异-0.07(95%CI -0.11至-0.03;P=0.003);开放手术组残疾更严重,在5周时世界卫生组织残疾评估量表2.0评分差异0.48(95%CI 0.15-0.73;P=0.003),在12周时差异0.38(95%CI 0.09-0.68;P=0.01);12周后差异不显著。
  • 在中位随访18.4个月(IQR 12.8-21.1)时,癌症复发(机器人组29/161[18%] vs 开放组25/156[16%])和总死亡率(机器人组23/161[14.3%] vs 开放组23/156[14.7%])无统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Robot-assisted radical cystectomy is being performed with increasing frequency, but it is unclear whether total intracorporeal surgery improves recovery compared with open radical cystectomy for bladder cancer. OBJECTIVES: To compare recovery and morbidity after robot-assisted radical cystectomy with intracorporeal reconstruction vs open radical cystectomy. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of patients with nonmetastatic bladder cancer recruited at 9 sites in the UK, from March 2017-March 2020. Follow-up was conducted at 90 days, 6 months, and 12 months, with final follow-up on September 23, 2021. INTERVENTIONS: Participants were randomized to receive robot-assisted radical cystectomy with intracorporeal reconstruction (n = 169) or open radical cystectomy (n = 169). MAIN OUTCOMES AND MEASURES: The primary outcome was the number of days alive and out of the hospital within 90 days of surgery. There were 20 secondary outcomes, including complications, quality of life, disability, stamina, activity levels, and survival. Analyses were adjusted for the type of diversion and center. RESULTS: Among 338 randomized participants, 317 underwent radical cystectomy (mean age, 69 years; 67 women [21%]; 107 [34%] received neoadjuvant chemotherapy; 282 [89%] underwent ileal conduit reconstruction); the primary outcome was analyzed in 305 (96%). The median number of days alive and out of the hospital within 90 days of surgery was 82 (IQR, 76-84) for patients undergoing robotic surgery vs 80 (IQR, 72-83) for open surgery (adjusted difference, 2.2 days [95% CI, 0.50-3.85]; P = .01). Thromboembolic complications (1.9% vs 8.3%; difference, -6.5% [95% CI, -11.4% to -1.4%]) and wound complications (5.6% vs 16.0%; difference, -11.7% [95% CI, -18.6% to -4.6%]) were less common with robotic surgery than open surgery. Participants undergoing open surgery reported worse quality of life vs robotic surgery at 5 weeks (difference in mean European Quality of Life 5-Dimension, 5-Level instrument scores, -0.07 [95% CI, -0.11 to -0.03]; P = .003) and greater disability at 5 weeks (difference in World Health Organization Disability Assessment Schedule 2.0 scores, 0.48 [95% CI, 0.15-0.73]; P = .003) and at 12 weeks (difference in WHODAS 2.0 scores, 0.38 [95% CI, 0.09-0.68]; P = .01); the differences were not significant after 12 weeks. There were no statistically significant differences in cancer recurrence (29/161 [18%] vs 25/156 [16%] after robotic and open surgery, respectively) and overall mortality (23/161 [14.3%] vs 23/156 [14.7%]), respectively) at median follow-up of 18.4 months (IQR, 12.8-21.1). CONCLUSIONS AND RELEVANCE: Among patients with nonmetastatic bladder cancer undergoing radical cystectomy, treatment with robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy resulted in a statistically significant increase in days alive and out of the hospital over 90 days. However, the clinical importance of these findings remains uncertain. TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN13680280; ClinicalTrials.gov Identifier: NCT03049410.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Catto JWF, Khetrapal P, Ricciardi F, et al. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. JAMA. 2022. PMID: 35569079. doi:10.1001/jama.2022.7393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。